Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Sep 16, 2025 (13 months ago)

Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous use, Rx only, IntegraDose Compounding Services LLC, 719 Kasota Ave Se, Minneapolis, MN 55414-2842 NDC 71139-0012-1

Affected NDC 71139-0012-01

Compare with the code on your package — it is the most precise check available.

Drug: Oxytocin

Recalling firm
IntegraDose Compounding Services LLC
NDC code
71139-0012-1
Origin
MN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0015-2026 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Oxytocin recalls

See all
Class III · Low risk

Oxytocin synthetic

Labeling: Not Elsewhere Classified

Terminated Labeling / mix-up Denver Solutions, LLC DBA Leiters Health NDC 71449-157-70 D-0070-2024
Class II · Moderate risk

oxyTOCIN

Lack of Assurance of Sterility:Lack of validation data for sanitization cycles

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-1134-2023

Other recalls by IntegraDose Compounding Services LLC

All 2025 recalls